Home
Storia in 1 fonti
Maintaining weight loss in obesity goes beyond GLP-1s: ‘The hard work is just beginning’
Lifestyle intervention remains a core component of obesity management, alongside the emergence of more potent pharmacotherapy.The FDA approval of obesity drugs including semaglutide (Wegovy/Wegovy pill, Novo Nordisk), tirzepatide (Zepbound, Eli Lilly) and orforglipron (Foundayo, Eli Lilly) led to a surge in their use. However, health care professionals continue to emphasize the importance of
Raccontata da
healio.com
Timeline cronologica
- ·
Maintaining weight loss in obesity goes beyond GLP-1s: ‘The hard work is just beginning’
Lifestyle intervention remains a core component of obesity management, alongside the emergence of more potent pharmacotherapy.The FDA approval of obesity drugs including…
- ·
Do people with obesity need to take a GLP-1 for the rest of their life?
Obesity is a chronic disease. This statement is clearly at the heart of the answer to this question. When you look at the data in the STEP 1 trial extension, semaglutide (Wegovy,…